Aktis Oncology, Inc. (AKTS)
18.14
+0.40
(+2.23%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
0.00 (0.00%)
After-Hours: 16:26
Aktis Oncology Price to Book Value : 2.069 for Oct. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 2.024 |
| October 07, 2026 | 2.054 |
| October 06, 2026 | 2.038 |
| October 05, 2026 | 2.113 |
| October 02, 2026 | 2.113 |
| October 01, 2026 | 2.113 |
| September 30, 2026 | 2.222 |
| September 29, 2026 | 2.247 |
| September 28, 2026 | 2.208 |
| September 25, 2026 | 2.217 |
| September 24, 2026 | 2.240 |
| September 23, 2026 | 2.25 |
| September 22, 2026 | 2.523 |
| September 21, 2026 | 2.445 |
| September 18, 2026 | 2.496 |
| September 17, 2026 | 2.608 |
| September 16, 2026 | 2.591 |
| September 15, 2026 | 2.557 |
| September 14, 2026 | 2.644 |
| September 11, 2026 | 2.658 |
| September 10, 2026 | 2.732 |
| September 09, 2026 | 2.745 |
| September 08, 2026 | 2.855 |
| September 04, 2026 | 3.086 |
| September 03, 2026 | 3.041 |
| Date | Value |
|---|---|
| September 02, 2026 | 3.072 |
| September 01, 2026 | 2.965 |
| August 31, 2026 | 2.956 |
| August 28, 2026 | 2.942 |
| August 27, 2026 | 2.987 |
| August 26, 2026 | 3.025 |
| August 25, 2026 | 3.045 |
| August 24, 2026 | 2.964 |
| August 21, 2026 | 2.746 |
| August 20, 2026 | 2.738 |
| August 19, 2026 | 2.855 |
| August 18, 2026 | 2.852 |
| August 17, 2026 | 2.820 |
| August 14, 2026 | 2.844 |
| August 13, 2026 | 2.714 |
| August 12, 2026 | 2.738 |
| August 11, 2026 | 2.826 |
| August 10, 2026 | 2.750 |
| August 07, 2026 | 2.753 |
| August 06, 2026 | 2.674 |
| August 05, 2026 | 2.584 |
| August 04, 2026 | 2.606 |
| August 03, 2026 | 2.536 |
| July 31, 2026 | 2.518 |
| July 30, 2026 | 2.624 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.606 |
| Alnylam Pharmaceuticals, Inc. | 22.96 |
| Savara, Inc. | 7.042 |
| Vericel Corp. | 5.544 |
| Biogen, Inc. | 1.770 |
Price to Book Value Related Metrics
| PS Ratio | 98.62 |
| PEG Ratio | -0.0774 |
| Price | 18.14 |
| Earnings Yield | -7.60% |
| Market Cap | 1.003B |
| PEGY Ratio | -0.0774 |